CHKB-CPT1B

Across TCGA pan-cancer cohorts, CHKB-CPT1B RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of CHKB-CPT1B’s most consistent transcriptional readouts.

The strongest signal is observed in bladder urothelial carcinoma (BLCA), where CHKB-CPT1B RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CHKB-CPT1B is over-expressed in tumor.

BLCA, UCEC, and THCA are the cancer types where CHKB-CPT1B tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in CHKB-CPT1B RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BLCA	All	All	+0.670	<.001	9	view →
UCEC	All	All	+0.445	.001	6	view →
THCA	All	All	+0.390	<.001	6	view →
LUSC	Male	All	+0.354	<.001	5	view →
LIHC	All	All	+0.098	.011	5	view →
STAD	All	All	+0.265	.008	4	view →
KIRC	All	All	+0.120	.004	4	view →
CHOL	All	All	+0.815	<.001	3	view →
READ	All	All	+0.426	<.001	2	view →
PRAD	All	All	+0.203	.001	2	view →
LUAD	All	All	+0.188	.002	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

CHKB-CPT1B–BLCA

Open the BLCA breakdown →